Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1403)
Drug Name
Remoxipride
Synonyms
Remoxiprida; Remoxiprida [INN-Spanish]; Remoxipride; Remoxipride [USAN:BAN:INN]; Remoxipridum; Remoxipridum [INN-Latin]; Romoxipride; Roxiam; (-)-(S)-3-Brom-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamid; (S)-3-Bromo-2,6-dimethoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; (S)-3-Bromo-N-((1-ethylpyrrolidin-2-yl)methyl)-2,6-dimethoxybenzamide; 0223RD59PE; 80125-14-0; A 33547; A-33547; BRN 4323708; CHEMBL22242; FLA 731; FLA-731; UNII-0223RD59PE
Indication Schizophrenia [ICD11: 6A20] Phase 4 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 371.27 Topological Polar Surface Area 50.8
Heavy Atom Count 22 Rotatable Bond Count 6
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
Cross-matching ID
PubChem CID
54477
PubChem SID
7980506 ; 8183659 ; 11112836 ; 11113786 ; 11466999 ; 11468119 ; 11486648 ; 12012970 ; 14755372 ; 17396851 ; 26751966 ; 34718458 ; 46508689 ; 47425546 ; 47425547 ; 47721872 ; 47945090 ; 47945091 ; 48095783 ; 49699324 ; 49875811 ; 50104640 ; 50409168 ; 57313624 ; 85788347 ; 85788802 ; 92308915 ; 99381443 ; 103189253 ; 103935779 ; 104304992 ; 117389433 ; 124886955 ; 126671568 ; 128007637 ; 134337624 ; 135014299 ; 137001507 ; 137263915 ; 144204485 ; 160963755 ; 163693566 ; 163853023 ; 170466425 ; 172860811 ; 176484143 ; 179151044 ; 198968595 ; 223541941 ; 223682010
ChEBI ID
CHEBI:92948
CAS Number
80125-14-0
TTD Drug ID
D01PIL
Formula
C16H23BrN2O3
Canonical SMILES
CCN1CCCC1CNC(=O)C2=C(C=CC(=C2OC)Br)OC
InChI
1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
InChIKey
GUJRSXAPGDDABA-NSHDSACASA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Remoxipride Metabolite FLA 838 DM004854
15565732
Oxidation - N-deethylation 1 [3] , [4]
Remoxipride Metabolite FLA 850 DM004857
15737595
Oxidation - Oxidationn 1 [3] , [4]
Remoxipride Metabolite FLA 853 DM004859
3435050
Oxidation - N-dealkylation 1 [3] , [4]
Unclear DM009999 N. A. Unclear 1 [2]
Remoxipride Metabolite NCL 118 DM004855
15737598
Oxidation - N-deethylation 2 [3] , [4]
Remoxipride Metabolite NCL 118 DM004855
15737598
Oxidation - Oxidationn 2 [3] , [4]
Remoxipride Metabolite NCM 001 DM004858
101532549
Oxidation - Hydrolyzationn 2 [3] , [4]
Remoxipride Metabolite NCM 009 DM004856
92287017
Oxidation - Hydrolyzationn 3 [3] , [4]
Remoxipride Metabolite NCM 009 DM004856
92287017
Oxidation - N-deethylation 3 [3] , [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR005227 Remoxipride Remoxipride Metabolite FLA 838 Oxidation - N-deethylation Unclear [3], [4]
MR005230 Remoxipride Remoxipride Metabolite FLA 850 Oxidation - Oxidationn Unclear [3], [4]
MR005234 Remoxipride Remoxipride Metabolite FLA 853 Oxidation - N-dealkylation Unclear [3], [4]
MR005235 Remoxipride Unclear Unclear CYP2D6 [2]
MR005228 Remoxipride Metabolite FLA 838 Remoxipride Metabolite NCL 118 Oxidation - Oxidationn Unclear [3], [4]
MR005231 Remoxipride Metabolite FLA 850 Remoxipride Metabolite NCM 001 Oxidation - Hydrolyzationn Unclear [3], [4]
MR005233 Remoxipride Metabolite FLA 850 Remoxipride Metabolite NCL 118 Oxidation - N-deethylation Unclear [3], [4]
MR005229 Remoxipride Metabolite NCL 118 Remoxipride Metabolite NCM 009 Oxidation - Hydrolyzationn Unclear [3], [4]
MR005232 Remoxipride Metabolite NCM 001 Remoxipride Metabolite NCM 009 Oxidation - N-deethylation Unclear [3], [4]
⏷ Show the Full List of 9 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
References
1 Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist. CNS Drug Rev. 2001 Fall;7(3):265-82.
2 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
3 Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors
4 The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.